Literature DB >> 1334098

Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.

K Gijbels1, S Masure, H Carton, G Opdenakker.   

Abstract

A substrate conversion assay was used to detect gelatinase activity in the cerebrospinal fluid (CSF) of patients with various neurological disorders. Two main forms of gelatinase with an apparent molecular mass of 65 and 85 kDa, respectively, could be discerned. The high molecular mass gelatinase was detectable only in samples of patients with multiple sclerosis or other inflammatory neurological disorders. A statistically significant correlation was found between the level of the 85-kDa gelatinase and the CSF cytosis. This protease could play a role in the process of demyelination and breakdown of the blood-brain barrier in certain neurological disorders, such as multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334098     DOI: 10.1016/0165-5728(92)90192-n

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  49 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

4.  Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis.

Authors:  Ke-Min Chen; Jer-Yuh Liu; Shih-Chan Lai; Li-Sung Hsu; Hsiu-Hsiung Lee
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

5.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

6.  Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.

Authors:  A W Millar; P D Brown; J Moore; W A Galloway; A G Cornish; T J Lenehan; K P Lynch
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 7.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

8.  Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.

Authors:  Youngpyo Nam; Jong-Heon Kim; Minchul Seo; Jae-Hong Kim; Myungwon Jin; Sangmin Jeon; Jung-wan Seo; Won-Ha Lee; So Jin Bing; Youngheun Jee; Won Kee Lee; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

9.  Association of matrix metalloproteinase-9 in eosinophilic meningitis of BALB/c mice caused by Angiostrongylus cantonensis.

Authors:  H H Lee; H L Chou; K M Chen; S C Lai
Journal:  Parasitol Res       Date:  2004-09-21       Impact factor: 2.289

10.  Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells.

Authors:  Gabriel M Gordon; Dolena R Ledee; William J Feuer; M Elizabeth Fini
Journal:  J Cell Physiol       Date:  2009-11       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.